314130 — Genome&Company Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual cashflow statement for Genome&Company, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-31,186	-36,004	-56,950	-50,653	-26,850
Depreciation
Amortisation
Non-Cash Items	11,809	5,659	5,632	9,645	5,806
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-890	2,048	5,855	1,737	5,988
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-18,803	-25,705	-36,002	-30,998	-7,609
Capital Expenditures	-1,829	-3,380	-7,276	-19,043	-4,186
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	4,009	-56,430	894	3,613	15,737
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	2,179	-59,810	-6,382	-15,430	11,551
Financing Cash Flow Items	—	57.7	35.6	0	-49.8
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	98,633	17,617	78,550	30,568	5,246
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	82,010	-67,898	36,167	-15,860	9,192